Nitric oxide-based therapy for erectile disorders

Drug Discovery Today: Therapeutic Strategies

Volumn 2, Issue 1, 2005, Pages 25-30

  Burnett, Arthur L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 3 [2 (4 CHLOROPHENYLTHIO)PHENYL] N (4 DIMETHYLAMINOBUTYL)ACRYLAMIDE; 4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDINE 3 YL]PYRIMIDIN 4 YLAMINE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ARGININE; COMPLEMENTARY DNA; GLYCEROL NITRATE; GUANYLATE CYCLASE ACTIVATOR; LINSIDOMINE; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE SODIUM; ORGANIC NITRATE; PAPAVERINE; PHOSPHODIESTERASE V INHIBITOR; S NITROSOTHIOL; SILDENAFIL; SILDENAFIL NITRATE; TADALAFIL; UNCLASSIFIED DRUG; VARDENAFIL;

ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SYNTHESIS; DRUG TARGETING; DYSPEPSIA; ERECTILE DYSFUNCTION; FLUSHING; FOOD DRUG INTERACTION; HEART INFARCTION; HUMAN; MALE; MOLECULAR DYNAMICS; NONHUMAN; NUCLEOTIDE SEQUENCE; ORTHOSTATIC HYPOTENSION; PAIN; PENIS ERECTION; PRIAPISM; RECURRENT DISEASE; REGULATORY MECHANISM; RHINITIS; SIDE EFFECT; SIGNAL TRANSDUCTION; SYSTEMIC DISEASE; VIRAL GENE DELIVERY SYSTEM;

EID: 21644458303     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2005.05.021     Document Type: Review

References (44)

1. No authors listed (1993) NIH consensus conference. Impotence. NIH consensus development panel on impotence. JAMA 270, 83-90
2. R.W. Lewis et al. Definitions, classification, and epidemiology of sexual dysfunction In T.F. Lue et al. eds. Sexual Medicine Sexual Dysfunction in Men and Women 2004 Health Publications pp 39-72
3. D.K. Montague et al. American Urological Association guideline on the management of priapism J. Urol. 170 2003 1318-1324
4. A.L. Burnett Pathophysiology of priapism: Dysregulatory erection physiology thesis J. Urol. 170 2003 26-34
5. A.L. Burnett Nitric oxide in the penis: Physiology and pathology J. Urol. 157 1997 320-324
6. K.J. Hurt et al. Akt-dependent phosphorylation of endothelial nitric-oxide synthase mediates penile erection Proc. Natl. Acad. Sci. USA 99 2002 4061-4066
7. J.D. Corbin et al. Cyclic GMP phosphodiesterase-5: Target of sildenafil J. Biol. Chem. 274 1999 13729-13732
8. P. Hedlund et al. Erectile dysfunction in cyclic CMP-dependent kinase I-deficient mice Proc. Natl. Acad. Sci. USA 97 2000 2349-2354
9. S.H. Francis et al. Cyclic nucleotide phosphodiesterases: Relating structure and function Prog. Nucleic Acid Res. Mol. Biol. 65 2001 1-52
10. M. Boolell et al. Sildenafil: An orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction Int. J. Impot. Res. 8 1996 47-52
11. I.V. Turko et al. Inhibition of cyclic GMP-binding cyclic GMP specific phosphodiesterase (type 5) by sildenafil and related compounds Mol. Pharmacol. 56 1999 124-130
12. R.C. Rosen et al. Overview of phosphodiesterase 5 inhibition in erectile dysfunction Am. J. Cardiol. 92 2003 9M-18M
13. A.D. Seftel Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles Clin. Cardiol. 27 2004 I14-I19
14. H. Padma-Nathan et al. Efficacy and safety of oral sildenafil in the treatment of erectile dysfunction: A double-blind, placebo-controlled study of 329 patients study group Sildenafil Int. J. Clin. Pract. 52 1998 375-379
15. G.B. Brock et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: Results of integrated analyses J. Urol. 168 2005 1332-1336
16. H. Porst et al. The efficacy and tolerability of vardenafil, a new, oral, elective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: The first at-home clinical trial Int. J. Impot. Res. 13 2001 192-199
17. T. Noto et al. Potentiation of penile tumescence by T-1032, a new potent and specific phosphodiesterase type V inhibitor, in dogs J. Pharmacol. Exp. Ther. 294 2000 870-875
18. K.K. Kang et al. DA-8159, a new PDE5 inhibitor, induces penile erection in conscious and acute spinal cord injured rabbits Eur. Urol. 43 2003 486-495
19. M. Seidler et al. In vitro effects of a novel class of nitric oxide (NO) donating compounds on isolated human erectile tissue Eur. Urol. 42 2002 523-528
20. J.S. Kalsi et al. NCX-911, a novel nitric oxide-releasing PDE5 inhibitor relaxes rabbit corpus cavernosum in the absence of endogenous nitric oxide Int. J. Impot. Res. 16 2004 195-200
21. N.N. Kim et al. Cross-regulation of intracellular cGMP and cAMP in cultured human corpus cavernosum smooth muscle cells Mol. Cell Biol. Res. Commun. 4 2000 10-14
22. V.K. Gopal et al. Allosteric sites of phosphodiesterase-5 (PDE5). A potential role in negative feedback regulation of cGMP signaling in corpus cavernosum Eur. J. Biochem. 268 2001 3304-3312
23. C.S. Lin et al. Identification and regulation of human PDE5A gene promoter Biochem. Biophys. Res. Commun. 280 2001 684-692
24. H.C. Champion et al. Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism Proc. Natl. Acad. Sci. USA 102 2005 1661-1666
25. D. Behr-Roussel et al. Chronic sildenafil improves erectile function and endothelium-dependent cavernosal relaxations in rats: Lack of tachyphylaxis Eur. Urol. 47 2005 87-91
26. B. Musicki et al. Erection capability is potentiated by chronic sildenafil treatment: Role of blood flow-induced endothelial nitric oxide synthase phosphorylation Mol. Pharmacol. 2005 (Epub ahead of print)
27. J.D. Brioni et al. Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction Int. J. Impot. Res. 14 2002 8-14
28. A. Mulsch et al. Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to ntirovasodilators Br. J. Pharmacol. 120 1997 681-689
29. P. Wohlfart et al. Release of nitric oxide from endothelial cells stimulated by YC-1, an activator of soluble guanylyl cyclase Br. J. Pharmacol. 128 1999 1316-1322
30. H. Mizusawa et al. Nitric oxide independent activation of guanylate cyclase by YC-1 causes erectile responses in the rat J. Urol. 167 2002 2276-2281
31. G.C. Hsieh et al. YC-1 potentiates the nitric oxide/cyclic GMP pathway in corpus cavernosum and facilitates penile erection in rats Eur. J. Pharmacol. 458 2003 183-189
32. J.P. Stasch et al. NO-independent regulatory site on soluble guanylate cyclase Nature 410 2001 212-215
33. J.S. Kalsi et al. BAY41-2272, a novel nitric oxide independent soluble guanylate cyclase activator, relaxes human and rabbit corpus cavernosum in vitro J. Urol. 169 2003 761-766
34. L.N. Miller et al. A-350619: A novel activator of soluble guanylyl cyclase Life Sci. 72 2003 1015-1025
35. C.G. Stief et al. Preliminary results with the nitric oxide donor linsidomine chlorhydrate in the treatment of human erectile dysfunction J. Urol. 148 1992 1437-1440
36. F. Tarhan et al. Effect of intracavernosal sodium nitroprusside in impotence Urol. Int. 56 1996 211-214
37. Q. Fu et al. A clinical comparative study on effects of intracavernous injection of sodium nitroprusside and papaverine/phentolamine in erectile dysfunction patients Asian J. Androl. 2 2000 301-303
38. A.W. Zorgniotti et al. Effect of large doses of the nitric oxide precursor, l-arginine, on erectile dysfunction Int. J. Impot. Res. 6 1994 33-35
39. J. Chen et al. Effect of oral administration of high-dose nitric oxide donor l-arginine in men with organic erectile dysfunction: Results of a double-blind, randomized, placebo-controlled study BJU Int. 83 1999 269-273
40. S. Cellek et al. A Rho-kinase inhibitor, soluble guanylate cyclase activator and nitric oxide-releasing PDE5 inhibitor: Novel approaches to erectile dysfunction Expert Opin. Invest. Drugs 11 2002 1563-1573
41. H. Garban et al. Cloning of rat and human inducible penile nitric oxide synthase. Application for gene therapy of erectile dysfunction Biol. Reprod. 56 1997 954-963
42. S. Tirney et al. Nitric oxide synthase gene therapy for erectile dysfunction: Comparison of plasmid, adenovirus, and adenovirus-transduced myoblast vectors Mol. Urol. 5 2001 37-43
43. T.R. Magee et al. Gene therapy of erectile dysfunction in the rat with penile neuronal nitric oxide synthase Biol. Reprod. 67 2002 20-28
44. H.C. Champion et al. Gene transfer of endothelial nitric oxide synthase to the penis augments erectile responses in the aged rat Proc. Natl. Acad. Sci. USA 96 1999 11648-11652